AZD6482

For research use only.

Catalog No.S1462 Synonyms: KIN-193

22 publications

AZD6482 Chemical Structure

CAS No. 1173900-33-8

AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.

Size Price Stock Quantity  
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's AZD6482 has been cited by 22 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.
Targets
PI3Kβ [1]
(Cell-free assay)
PI3Kδ [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
PI3Kα [1]
(Cell-free assay)
10 nM 80 nM 420 nM 870 nM
In vitro

AZD6482 also inhibits PI3Kα, γ, and δ, with IC50 of 80 nM to 1.09 μM, which are significantly lower than its (+)-enantiomer (S-form). AZD6482 is an antiplatelet agent; it blocks platelet activation adhesion/aggregation and promotes platelet disaggregation in assay of washed platelet aggregation (WPA), with an IC50 value of 6 nM. Furthermore, by targeting PI3Kβ, AZD6482 specifically inhibits thrombosis without interfering with normal haemostasis. Therefore, AZD6482 is used as an anti-thrombotic drug for the prophylaxis of thrombotic disorders. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human RXF393 cell Mn\0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKGi3bXHuJHJZTjN7MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFEyPTRizszN NV\lOVVFW0GQR1XS
human SW982 cell NET5dWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2DuR2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA{PTh2IN88US=> NVji[ZA2W0GQR1XS
human MAD-MB-468 cells MV\GeY5kfGmxbjDhd5NigQ>? M37EbmlvcGmkaYTpc44hd2ZiUFmzT4JmfGFiaX6gbJVu[W5iTVHEMW1DNTR4ODDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOnckS3N{BCc3RicHjvd5Bpd3K7bHH0bY9vKGK7IHPlcIx2dGG{IIDveIVv[3liYYPzZZktKEmFNUC9NE4xPCEQvF2= NGfaN5EzPDl7Mki3OC=>
human KURAMOCHI cell NIP4PIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFviSY1KdmirYnn0bY9vKG:oIHj1cYFvKEuXUlHNU2NJUSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUC1NUDPxE1? NXznfnBlW0GQR1XS
human A498 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxO|k2KM7:TR?= MmPuV2FPT0WU
human YT cell MmrWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1Wze2lvcGmkaYTpc44hd2ZiaIXtZY4hYVRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGyNFY3KM7:TR?= Ml7GV2FPT0WU
human VMRC-RCZ cell M{XRSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF23WIJKdmirYnn0bY9vKG:oIHj1cYFvKF[PUlOtVmNbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNEi5PEDPxE1? M2fIWHNCVkeHUh?=
human MDA-MB-415 cell NHnZfmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1ziSWlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQyPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMU[3N|Ih|ryP MULTRW5ITVJ?
human J82 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF;zfoxKdmirYnn0bY9vKG:oIHj1cYFvKEp6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFc4PzlizszN MWfTRW5ITVJ?
human SW1710 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVI6OiEQvF2= M2PXUXNCVkeHUh?=
human T47D cell NU\2ZWRET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXfJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkWzNlch|ryP MkHOV2FPT0WU
human SU-DHL-1 cell NYqxSo9YT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFLSTndKdmirYnn0bY9vKG:oIHj1cYFvKFOXLVTIUE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53NkixN{DPxE1? M4HPVHNCVkeHUh?=
human BT-20 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGJVNTJyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVIzOiEQvF2= MVPTRW5ITVJ?
human OS-RC-2 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH64WXVKdmirYnn0bY9vKG:oIHj1cYFvKE:VLWLDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjZ{M{i4JO69VQ>? M{TJOHNCVkeHUh?=
human RPMI-6666 cell M1PO[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHvkfYFKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtOlY3PiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNkSzO|kh|ryP NWXjVZNuW0GQR1XS
human OVCAR-3 cell NVz4UmlET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1Pyb2lvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjd7NE[g{txO NH;V[WpUSU6JRWK=
human NALM-6 cell Ml:4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnIbY9KdmirYnn0bY9vKG:oIHj1cYFvKE6DTF2tOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzB2NkWg{txO NH\YRpFUSU6JRWK=
human RS4-11 cell MlX5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1j2ZWlvcGmkaYTpc44hd2ZiaIXtZY4hWlN2LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzhyNjFOwG0> MYnTRW5ITVJ?
human SK-MES-1 cell NIXXd2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYPUdGRtUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwN{i5Olch|ryP MYjTRW5ITVJ?
human ES7 cell M37hWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkPQTY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkixNlg3KM7:TR?= MofZV2FPT0WU
human NCI-H2342 cell M3PQSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUToTm9CUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki0Nlk1KM7:TR?= MVTTRW5ITVJ?
human SCC-9 cell Mn\IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXzT[YVEUW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDV5NzFOwG0> MXfTRW5ITVJ?
human EW-7 cell NFfBXoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoTmTY5pcWKrdHnvckBw\iCqdX3hckBGXy15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64OlM2PiEQvF2= MlrtV2FPT0WU
human HH cell MnPRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGrYVmVKdmirYnn0bY9vKG:oIHj1cYFvKEiKIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65OlIzOiEQvF2= NWX4UpJiW0GQR1XS
human A427 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUnsUnpSUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QTVyNTFOwG0> NGrqT|lUSU6JRWK=
human Daudi cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4nKNWlvcGmkaYTpc44hd2ZiaIXtZY4hTGG3ZHmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA3QDh6IN88US=> Mnm5V2FPT0WU
human P30-OHK cell NIrqc|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA4OTN6IN88US=> Mn20V2FPT0WU
human HGC-27 cell NFjkN4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo[wTY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVEvOThzNjFOwG0> NEnhfZdUSU6JRWK=
human CAMA-1 cell M37OfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWXCeWVFUW6qaXLpeIlwdiCxZjDoeY1idiCFQV3BMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJyMEGg{txO NIPOSnpUSU6JRWK=
human SK-OV-3 cell MoHxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH7rOIRKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJyNES0JO69VQ>? NHH1TIFUSU6JRWK=
human NCI-H1048 cell M4LK[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnewTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGwOFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ{NUe5JO69VQ>? MYjTRW5ITVJ?
human MEL-HO cell MmizS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJG1GVC2KTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlQzOzhizszN M2nYUnNCVkeHUh?=
human NKM-1 cell M1GyRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn3vTY5pcWKrdHnvckBw\iCqdX3hckBPU01vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlg3OzZizszN M1:2e3NCVkeHUh?=
human NCI-H650 cel MmLKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{ODB5NjFOwG0> NXrVPJB3W0GQR1XS
human HAL-01 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWHnTog2UW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNyMUe1JO69VQ>? Mki1V2FPT0WU
human 786-0 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zNVI5OyEQvF2= NGHYPVFUSU6JRWK=
human GI-1 cell NEDLbo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWr1WFJZUW6qaXLpeIlwdiCxZjDoeY1idiCJST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{OThyODFOwG0> MorUV2FPT0WU
human Becker cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVzFS4NHUW6qaXLpeIlwdiCxZjDoeY1idiCEZXPr[ZIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN4M{G1JO69VQ>? Mn2xV2FPT0WU
human CCF-STTG1 cell NInORWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUDEVZpxUW6qaXLpeIlwdiCxZjDoeY1idiCFQ1[tV3RVTzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkSyOVI2KM7:TR?= M4LyN3NCVkeHUh?=
human MC116 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYXJcohq[mm2aX;uJI9nKGi3bXHuJG1EOTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60OlEzOiEQvF2= NHPhVGJUSU6JRWK=
human MDA-MB-468 cell M2fCc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\3OXlKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk01PjhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkWzO|M3KM7:TR?= MUDTRW5ITVJ?
human NB12 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4\TemlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVQ5PDJizszN MnvIV2FPT0WU
human LXF-289 cell NF6wSmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3:zVWlvcGmkaYTpc44hd2ZiaIXtZY4hVFiILUK4PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTVzMESg{txO NH7MeVdUSU6JRWK=
human MFE-296 cell NULnWXpbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYexRnJjUW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlk3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53NkizOkDPxE1? NXvJ[Ig{W0GQR1XS
human SNU-423 cell MkK5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3zs[2lvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUSyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTdzOUKg{txO NGPyV5RUSU6JRWK=
human NCI-H2291 cell NWjnRotpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXXWUmJyUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIzQTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW3OlEh|ryP NXf5Uo9EW0GQR1XS
human OCUB-M cell MnPKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYrLOWRWUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjV6M{G0JO69VQ>? NESyNmdUSU6JRWK=
human KU812 cell M4HBRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PZU2lvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU6PjJ6IN88US=> M{\LfXNCVkeHUh?=
human HuO9 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXPXoRKdmirYnn0bY9vKG:oIHj1cYFvKEi3T{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyOjhizszN MYXTRW5ITVJ?
human 639-V cell NH[0TnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlHKTY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlMyPDRizszN NIfsXmdUSU6JRWK=
human HCC70 cell M4\KVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDTT21KdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{ewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PjF2NjFOwG0> M3rMbnNCVkeHUh?=
human SNB75 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLTcYVKdmirYnn0bY9vKG:oIHj1cYFvKFOQQke1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PjVyODFOwG0> MUPTRW5ITVJ?
human D-336MG cell NWX2OVNHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlO4TY5pcWKrdHnvckBw\iCqdX3hckBFNTN|Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43Pjh6IN88US=> NXWyVHpJW0GQR1XS
human LoVo cell M3P1Xmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXzjfnZCUW6qaXLpeIlwdiCxZjDoeY1idiCOb2\vJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44Ozh{NTFOwG0> NYH0R49sW0GQR1XS
human EB2 cell NIO1d|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmnGTY5pcWKrdHnvckBw\iCqdX3hckBGSjJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLke1NFE6KM7:TR?= MYTTRW5ITVJ?
human HSC-2 cell NIDOfFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkPJTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|U4OjdizszN M{TUU3NCVkeHUh?=
human D-542MG cell NGTrenlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1jK[GlvcGmkaYTpc44hd2ZiaIXtZY4hTC13NELNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQDVyN{eg{txO NXLzS4N[W0GQR1XS
human COLO-684 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mkj2TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjByM{Kg{txO NFuzZ49USU6JRWK=
human GDM-1 cell NFfJVYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4D3UGlvcGmkaYTpc44hd2ZiaIXtZY4hT0SPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI1OjB4IN88US=> MmHtV2FPT0WU
human SW1088 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOFgyPDNizszN MWDTRW5ITVJ?
human SF295 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFm2SWdKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44Pjl3NTFOwG0> NWXyVppPW0GQR1XS
human NCI-H2030 cell NH7JNmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEO5cFFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUCyPFgh|ryP NFfBblRUSU6JRWK=
human NCI-H1755 cell Mnu4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjdyNkOg{txO NWXQXlVrW0GQR1XS
human MDA-MB-361 cell NEXqNmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXHjRmRFUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61NlcxQSEQvF2= MUnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:[1]
- Collapse

Assay of PI3K enzyme inhibition:

The inhibition of PI3Kβ, PI3Kα, PI3Kγ, and PI3Kδ is evaluated in an AlphaScreen based enzyme activity assay using human recombinant enzymes. The assay measures PI3K-mediated conversion of PIP2 to PIP3. Biotinylated PIP3, a GST-tagged pleckstrin homology (PH) domain and the two AlphaScreen beads form a complex that elicits a signal upon laser excitation at 680 nm. The PIP3 formed in the enzyme reaction competes with the biotinylated PIP3 for binding to the PH domain thus reducing the signal with increasing enzyme product. The AZD6482 is dissolved in DMSO and added to 384 well plates. PBKβ, PBKα, PBKγ, or PBKδ is added in a Tris buffer (50 mM Tris pH 7.6, 0.05% CHAPS, 5 mM DTT, and 24 mM MgCl2) and allowed to preincubate with AZD6482 for 20 minutes prior to the addition of substrate solution containing PIP2 and ATP. The enzyme reaction is stopped after 20 minutes by addition of stop solution containing EDTA and biotin-PIP3, followed by addition of detection solution containing GST-grpl PH and AlphaScreen beads. Plates are left for a minimum of 5 hours in the dark prior to analysis. The final concentration of DMSO, ATP and PIP2 in the assay are, 0.8%, 4 μM, and 40 μM, respectively. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
Cell Research:[1]
- Collapse
  • Cell lines: Human platelet pellet
  • Concentrations: 0–60 nM, dissolved in DMSO
  • Incubation Time: 5 min
  • Method: For assay of washed platelet aggregation (WPA), the platelet pellets are isolated from human blood and re-suspended to 2 × 1015/L in Tyrodes buffer (TB) containing 1 μM hirudin and 0.02 U/mL apyrase. Then, the platelet suspension is left to rest at room temperature for 30 min. Just prior to time for assay, CaCl2 is added to a final concentration of 2 mM. AZD6482, dissolved in DMSO, is added to a 96-well plate prior to the addition of the washed platelet suspension. The platelet suspension is preincubated with AZD6482 for 5 min. Light absorption at 650 nm is recorded before and after a 5 min plate shake and referred to as recording 0 (R0) and Rl. A mouse anti-human CD9 antibody is added (at a donor specific concentration) to each well prior to next 10 min plate shake and light absorption recording; R2. For data analysis, light absorbance in wells with TB are subtracted from all readings before percent aggregation is calculated according the formula: [(R1-R2)/R1] × 100 = % aggregation. Spontaneous aggregation or pro-aggregatory effect of the inhibitor is evaluated by the same formula, [(R0-Rl)/R0] × 100 = % aggregation. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (200.75 mM)
Ethanol 10 mg/mL (24.48 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 408.45
Formula

C22H24N4O4

CAS No. 1173900-33-8
Storage powder
in solvent
Synonyms KIN-193
Smiles CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy AZD6482 | AZD6482 supplier | purchase AZD6482 | AZD6482 cost | AZD6482 manufacturer | order AZD6482 | AZD6482 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID